Source-grounded facts extracted from ALUMIS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ALUMIS INC. reported the quarter ended March 31, 2026 results: revenue $1.7 million, net income $93.1 million.
“Quarter 2026 Financial Results ● As of March 31, 2026, Alumis had cash, cash equivalents and marketable securities of $569.5 million. ● Revenue included collaboration revenue of $1.7 million for the three months ended March 31, 2026, compared to license revenue of $17.4 million for the three months ended March 31, 2025, related to the collaboration and licensing”
ALUMIS INC. reported the year ended December 31, 2025 results: revenue license revenue of $17.4 million and collaboration revenue of $6.7 million, net income Net loss was $243.3 million.
“Revenue included license revenue of $17.4 million and collaboration revenue of $6.7 million for the year ended December 31, 2025, related to the collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. ● Research and development expenses were $386.0 million for the year ended December 31, 2025, compared to $265.6 million for the year ended December 31, 2024. The increase was primarily driven by contract research and clinical trial costs for the envudeucitinib and other programs, including costs to support acceleration of clinical trial activities for the Phase 3 ONWARD clinical program, as well as increased headcount to support development efforts and severance costs, including stock-based compensation expense, related to the merger with ACELYRIN. The year ended December 31, 2024 included a clinical milestone payment of $23.0 million related to the prior acquisition of FronThera. ● General and administrative expenses were $91.9 million for the year ended December 31, 2”
ALUMIS INC. completed an acquisition involving ACELYRIN, Inc. for 0.4814 shares of voting common stock of Alumis (closed 2025-05-21).
“hich was subsequently amended on April 20, 2025 (the “ Merger Agreement ”) with ACELYRIN, Inc., a Delaware corporation (“ ACELYRIN ”), and Arrow Merger Sub, Inc., a Delaware corporation and a direct wholly owned”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.